University of Kentucky awarded $6 million for GDNF and related research

September 12, 2005

The University of Kentucky Morris K. Udall Parkinson's Disease Research Center of Excellence has been awarded nearly $6 million from National Institutes of Health and National Institute of Neurological Disorders and Stroke to continue work on the promising drug glial cell line-derived neurotrophic factor (GDNF) and similar compounds.

Greg Gerhardt, Ph.D., professor, Department of Anatomy and Neurobiology and Department of Neurology, director of the Morris K. Udall Parkinson's Disease Research Center of Excellence, and director of the Center for Sensor Technology, has headed the Udall Center at UK since its inception six years ago. As one of only 12 Udall Centers in the nation, UK's center represents the leading edge of research into Parkinson's disease, which at this point remains an incurable condition.

GDNF differs from other Parkinson's therapies in that it has demonstrated potential to halt or perhaps reverse the neurodegenerative condition. Current treatments only provide temporary relief from symptoms.

"The NINDS is pleased to continue the support of the University of Kentucky Udall Center, a unique component of the Udall center program that provides non-human primate studies of potential therapeutics in Parkinson's disease," said Diane Murphy, Ph.D., Program Director for the NINDS' Morris K. Udall Parkinson's Disease Research Centers of Excellence.

Gerhardt and colleagues will spend the next five years investigating potential negative effects of GDNF, and how to fine tune dosing and administration techniques to make the therapy a safer and more viable alternative.

The $6 million funding from NIH represents a vote of confidence for the UK Udall Center and its work to date on GDNF and related molecules. At the end of this five-year funding cycle UK researchers plan to be ready to move GDNF or a related compound once again into human clinical trials - a timetable considered ambitious by industry standards, but realistic to Gerhardt.

UK's research into GDNF made headlines recently when the CBS news show "60 Minutes" broadcast a feature on the controversy that arose when Kentucky and New York patients enrolled in a national Phase 1 clinical trial for the drug were left without medical treatment or legal recourse when Amgen, Inc., the biotech firm that holds the patent for GDNF, suddenly withdrew the drug from testing amidst allegations of safety and efficacy concerns.

Amgen's own bioethicist told CBS that the decision was largely a result of a nervous pharmaceutical industry haunted by the specter of the Vioxx lawsuits. CBS also uncovered video footage in which an Amgen executive stated that the treatment in its current incarnation, a complex procedure involving deep brain surgery, would not be a money maker for the corporation. Shortly after halting the trial and withdrawing all GDNF treatment from patients, Amgen applied for a new patent on a different form of GDNF that could potentially be delivered in a more economical capsule form.

Despite the requests of investigators, the pleas of patients and the approval of the Food and Drug Administration, Amgen has refused to provide the drug under compassionate use guidelines to those patients who had undergone surgery to implant a pump and catheter in their brains, and had been receiving GDNF successfully for as long as two years. Court cases in Kentucky and New York have been dismissed and appeals are being considered.

While distinctly troubled by the plight of patients caught in the crossfire of the first GDNF trials, Gerhardt says Parkinson's researchers are far from giving up all hope in GDNF. He continues to work with the drug in animal models, and to explore similar molecules to which Amgen does not possess patent rights. By exploring multiple paths of research at once, Gerhardt and his colleagues are applying the old maxim "don't put all your eggs in one basket," to the newest science imaginable.

"History is riddled with examples of technology that failed more than once before being perfected. The Wright brothers crashed a few airplanes. GDNF has not failed so spectacularly, although we still have much to learn about it. We're going to spend the next five years studying the technology and how to translate it into clinical use in patients," said Gerhardt.
-end-
The GDNF trial launched at UK in 2002, and was headed by principal investigator John Slevin, M.D., professor in the UK Department of Neurology and Department of Pharmacology and director of the Movement Disorders Clinic at UK; Gerhardt; Don Gash, Ph.D., the UK Alumni Chair in Anatomy and Neurobiology, professor in the Department of Anatomy and Neurobiology, and director of the M. Margrite Davis-Ralph E. Mills Magnetic Resonance Imaging and Spectroscopy Center at UK; Byron Young, M.D., the Johnston-Wright Endowed Chair of Surgery, professor, Department of Surgery, and chief, Division of Neurosurgery, associate dean for Clinical Affairs, and chief of staff, UK Hospital. Ten patients participated in the trial through UK, joining approximately 40 others in the United States and the United Kingdom.

University of Kentucky

Related Neurological Disorders Articles from Brightsurf:

Significant link found between air pollution and neurological disorders
Air pollution was significantly associated with an increased risk of hospital admissions for several neurological disorders, including Parkinson's disease, Alzheimer's disease, and other dementias, in a large, long-term study of US adults.

COVID-19 frequently causes neurological injuries
Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows.

Neurological consequences of COVID-19: The 'Silent Wave'
Is the world prepared a wave of neurological consequences that may be on its way as a result of COVID-19?

New smart drug delivery system may help treatment for neurological disorders
A Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders.

Roadmap for linking neurological and locomotor deficits
Scientists capture highly-detailed ''locomotor signatures'' of mouse models of neurological disease.

Scientists replace malfunctioning 'vacuum cleaner' cells linked to neurological disorders
Malfunctioning microglia are associated with a range of neurological diseases.

Exploring the neurological impact of air pollution
Air pollution has become a fact of modern life, with a majority of the global population facing chronic exposure.

Mole-rats' failure to social distance offers clue for treating some neurological disorders
A new study into why African naked mole-rats shun social distancing in favor of crowded sleeping arrangements provides insight into what may be occurring in the brains of people with certain neurological conditions, including autism spectrum disorder, epilepsy, and schizophrenia.

Maternal hypertensive disorders may lead to mental health disorders in children
Hypertensive pregnancy disorders, especially preeclampsia -- may increase the risk of psychological development disorders and behavioral and emotional disorders in children.

Probiotic intervention in ameliorating the altered CNS functions in neurological disorders
The review aims at giving a comprehensive analysis of the studies performed on animals and humans and discusses the findings in different neurological and psychiatric disorders (Anxiety, Major Depressive disorder, bipolar disorder, schizophrenia, autism spectrum disorder, cognitive impairments etc).

Read More: Neurological Disorders News and Neurological Disorders Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.